CTRI/2017/06/008950
Active, not recruiting
未知
A Study to Evaluate the Efficacy and Safety of Metaderm M1 and Metaderm M5 Cream Formulas in Patients with Moderate to Severe Atopic Dermatitis - NI
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Haus Bioceuticals Inc
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Moderate to severe atopic dermatitis as determined by Physicianâ??s Global Assessment (PGA \> 3\) and SCORAD \> 25 (SCORAD and PGA will incorporate whole body assessments)
- •2\)Males and females, age 12 \- 65 years old inclusive
Exclusion Criteria
- •1\) Is currently participating or has participated in another interventional clinical study at this or any other facility in the past 3 months.
- •2\) Currently or has been diagnosed/treated for cancer in the past 5 years.
- •3\) Requires any topical or systemic medications that could affect the course of their atopic dermatitis during the study period (except inhaled steroids and/or antihistamines for asthma or allergies).
- •4\) Has a known hypersensitivity to any corticosteroid creams.
- •5\) Has any active infections or has used antibiotics in the past 7 days.
- •6\) Has any physical attributes or skin conditions that might interfere with the clear visual or instrumental assessments.(i.e. cuts, sunburn, birth marks, tattoos, extensive scarring, excessive hair growth or acne)
- •7\) Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the
- •study results.
- •8\)Has used any immunosuppressant drugs or immunotherapy within the past 30 days or 5 half\-lives.
- •9\) Is an employee of the sponsor company or clinical testing site.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
A clinical trial to study the effects of two drugs, Metformin Immediate Release and Metformin Extended Release in newly diagnosed type 2 diabetes mellitus patients.Health Condition 1: E119- Type 2 diabetes mellitus without complicationsCTRI/2021/04/033194Bangalore Medical College and Research Institute70
Recruiting
Phase 3
Metformin and Body Mass Index of Patients under Treatment with SSRICondition 1: Obesity. Condition 2: Depression. Condition 3: Anxiety Disorders.Drug-induced obesityMajor depressive disorder, single episode, severe without psychotic featuresOther anxiety disordersE66.1F32.2IRCT20140102016035N3Rasht University of Medical Sciences60
Not yet recruiting
Not Applicable
To evaluate the efficacy of two drugs methylprednisolone and etoricoxib in laproscopic surgeryHealth Condition 1: O- Medical and SurgicalCTRI/2019/03/018041Department of anaesthesiology Jln Medical College ajmer
Completed
Phase 3
Effect of methylene blue on treatment of COVID-19 patientsIRCT20191228045924N1Mashhad University of Medical Sciences80
Completed
Phase 2
Comparison between the effectiveness of methadone & Acceptance & Commitment group combination therapy & methadone therapy in the prevention rate of relapse in people with opium abuse.Mental & behavioural disorders due to use of opioids.Mental and behavioural disorders due to use of opioidsIRCT2016062328603N1Vice chancellor for research Zanjan University of Medical Sciences30